Our research projects

Immunotherapy could be a potential treatment for ependymoma. To make immunotherapy effective we need to know more about how ependymoma works.

Half of patients Ependymoma (EPN) with no disease after treatment on MRI relapse within 2 years. This suggests that they have low level or minimal residual disease (MRD). Developing an accurate MRD detection test could help improve survival.

This work focuses on defining how a new oncoprotein (called CARM1) we have discovered in neuroblastoma cells helps the cancer cells to survive, grow and avoid death.

Craniopharyngioma, a brain tumour affecting children, is difficult to treat. Work within the laboratories of the investigators has identified potential drugs that could turn off tumour growth. These drugs will be tested in patients whose tumours have regrown in a clinical trial.

Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.

Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma

Enhancing CAR T-cell expansion and prolonged persistence for the effective treatment of paediatric medulloblastoma

What helps and what hinders in remotely delivered acceptance and commitment therapy for survivors of childhood brain tumours: a diary and interview study.

Living with treatment-related hearing loss: Experiences of survivors of childhood brain cancer